Docetaxel is currently indicated for androgen-independent, metastatic prostate cancer; there is also evidence demonstrating the role of CYP1B1 in modulating the activity of the drug. We present the case of a man with residual disease after radical prostatectomy treated successfully with docetaxel chemotherapy. After only two cycles of therapy, a complete remission was obtained and then consolidated with additional cycles of docetaxel and radiotherapy. Prospective genetic analysis had shown that the patient had a favourable CYP1B1 genotype. He has been disease free since August 2006. Prospective trials investigating this strategy are warranted.
BRANDI G, DE ROSA F, DANESI R, MONTINI GC, BIASCO G (2008). Durable Complete Response to Frontline Docetaxel in an Advanced Prostate Cancer Patient with Favourable CYP1B1 Isoforms: Suggestion for Changing Paradigms?. EUROPEAN UROLOGY, 54(4), 938-941 [10.1016/j.eururo.2008.07.029].
Durable Complete Response to Frontline Docetaxel in an Advanced Prostate Cancer Patient with Favourable CYP1B1 Isoforms: Suggestion for Changing Paradigms?
BRANDI, GIOVANNI;BIASCO, GUIDO
2008
Abstract
Docetaxel is currently indicated for androgen-independent, metastatic prostate cancer; there is also evidence demonstrating the role of CYP1B1 in modulating the activity of the drug. We present the case of a man with residual disease after radical prostatectomy treated successfully with docetaxel chemotherapy. After only two cycles of therapy, a complete remission was obtained and then consolidated with additional cycles of docetaxel and radiotherapy. Prospective genetic analysis had shown that the patient had a favourable CYP1B1 genotype. He has been disease free since August 2006. Prospective trials investigating this strategy are warranted.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
